Inflammation regulates fibroblast growth factor 23 production

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 4, 2016, Pages 325-332

  Francis, Connor ^a,b   David, Valentin ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chronic kidney disease; fibroblast growth factor 23; hypoxia inducible factor 1; inflammation; iron deficiency

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; HYPOXIA INDUCIBLE FACTOR 1ALPHA; FIBROBLAST GROWTH FACTOR; HIF1A PROTEIN, HUMAN; IRON; PHOSPHORUS; VITAMIN D;

BONE METABOLISM; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; MINERAL METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REGULATORY MECHANISM; REVIEW; BONE; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE EXACERBATION; DISEASES; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; METABOLISM; OSTEOBLAST; OSTEOCYTE;

BONE AND BONES; DISEASE; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; IRON; OSTEOBLASTS; OSTEOCYTES; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84969268627     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000232     Document Type: Review

References (89)

1. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92:131-155.
2. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568.
3. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390.
4. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18:2116-2124.
5. David V, Dai B, Martin A, et al. Calcium regulates FGF-23 expression in bone. Endocrinology 2013; 154:4469-4482.
6. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17:1305-1315.
7. Lopez I, Rodriguez-Ortiz ME, Almaden Y, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80:475-482.
8. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. JBiolChem2003; 278:37419-37426.
9. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291:E38-E49.
10. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20:302-308.
11. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277:494-498.
12. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288-296.
13. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
14. Stubbs JR, He N, Idiculla A, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Min Res 2012; 27:38-46.
15. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82:737-747.
16. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
17. Isakova T, Houston J, Santacruz L, et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol 2013; 28:2035-2042.
18. Kovesdy CP, Quarles LD. The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract 2013; 123:194-201.
19. Prie D, Forand A, Francoz C, et al. Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the livertransplant waiting list. PLoS One 2013; 8:e66182.
20. Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304:E863-E873.
21. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956-966.
22. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
23. Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22:1020-1032.
24. David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2015; 89:135-146.
25. Ito N, Wijenayaka AR, Prideaux M, et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol 2015; 399:208-218.
26. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281:18370-18377.
27. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
28. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
29. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179-3182.
30. Bergwitz C, Banerjee S, Abu-Zahra H, et al. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab 2009; 94:4267-4274.
31. Yancovitch A, Hershkovitz D, Indelman M, et al. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J Bone Min Metab 2011; 29:621-625.
32. Tagliabracci VS, Engel JL, Wiley SE, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 2014; 111:5520-5525.
33. Wang X, Wang S, Li C, et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 2012; 8:e1002708.
34. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663.
35. Martin A, David V, Li H, et al. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice. Mol Endocrinol 2012; 26:1883-1895.
36. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108:E1146-E1155.
37. Imel EA, Peacock M, Gray AK, et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011; 96:3541-3549.
38. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet 2010; 282:577-580.
39. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Min Res 2013; 28:1793-1803.
40. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009; 201:309-320.
41. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92:1157-1163.
42. Compston JE, Vedi S, Croucher PI, et al. Bone turnover in nonsteroid treated rheumatoid arthritis. Ann Rheum Dis 1994; 53:163-166.
43. Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25:1282-1289.
44. Robinson RJ, Iqbal SJ, Abrams K, et al. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12:699-705.
45. Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 2003; 30:2365-2368.
46. Schwartz A, Brotfain E, Koyfman L, et al. Association between hypophosphatemia and cardiac arrhythmias in the early stage of sepsis: could phosphorus replacement treatment reduce the incidence of arrhythmias? Electrolyte Blood Press 2014; 12:19-25.
47. Schwartz A, Gurman G, Cohen G, et al. Association between hypophosphatemia and cardiac arrhythmias in the early stages of sepsis. Eur J Intern Med 2002; 13:434.
48. Navarro-Gonzalez JF, Mora-Fernandez C, Muros M, et al. Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol 2009; 4:1646-1654.
49. Yamada S, Tokumoto M, Tatsumoto N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 2014; 306:F1418-F1428.
50. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26:662-687.
51. Lemire JM. Immunomodulatory role of 1, 25-dihydroxyvitamin D3. J Cell Biochem 1992; 49:26-31.
52. Puts MT, Visser M, Twisk JW, et al. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol 2005; 63:403-411.
53. Oelzner P, Muller A, Deschner F, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62:193-198.
54. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-65.
55. Hillman L, Cassidy JT, Johnson L, et al. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 1994; 124:910-916.
56. Dounousi E, TorinoC, Pizzini P, et al. Intact FGF23 and alpha-klotho during acute inflammation/sepsis in CKD patients. Eur J Clin Invest 2016; 46:234-241.
57. Sato H, James Kazama J, Murasawa A, et al. Serum fibroblast growth factor 23 (FGF23) in patients with rheumatoid arthritis. Intern Med (Tokyo, Japan) 2016; 55:121-126.
58. Hanks LJ, Casazza K, Judd SE, et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 2015; 10:e0122885.
59. Holecki M, Chudek J, Owczarek A, et al. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol 2015; 82:900-909.
60. Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162.
61. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008; 3:e3740.
62. El-Hodhod MA, Hamdy AM, Abbas AA, et al. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol 2012; 12:44.
63. Yan L, Bowman MA. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. Inflamm Cell Signal 2014; 1: e279. doi: 10. 14800/ics. 279.
64. Yamazaki M, Kawai M, Miyagawa K, et al. Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation. J Bone Min Metab 2015; 33:342-354.
65. Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 2015; 290:10447-10459.
66. Kitaoka T, Namba N, Miura K, et al. Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. J Bone Min Metab 2011; 29:598-605.
67. Braithwaite V, Prentice AM, Doherty C, Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012; 2012:27.
68. Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014; 29:263-273.
69. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014; 28:671-681.
70. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Min Res 2014; 29:361-369.
71. Colgan SP, Eltzschig HK. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Ann Rev Physiol 2012; 74:153-175.
72. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114:1098-1106.
73. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 2006; 66:2600-2607.
74. Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood 2004; 103:1124-1130.
75. Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453:807-811.
76. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103:18154-18159.
77. Kuhlicke J, Frick JS, Morote-Garcia JC, et al. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007; 2:e1364.
78. McMahon S, Grondin F, McDonald PP, et al. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 2005; 280:6561-6569.
79. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Renal Nutr 2003; 13:144-148.
80. Stenvinkel P. Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant 2001; 16:1968-1971.
81. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purification 2001; 19:53-61.
82. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154:882-892.
83. Herbelin A, Urena P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954-960.
84. Bolton CH, Downs LG, Victory JG, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001; 16:1189-1197.
85. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the longterm risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 2011; 80:1231-1238.
86. Dai B, David V, Martin A, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7:e44161.
87. Christov M, Waikar SS, Pereira RC, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84:776-785.
88. Han X, Li L, Yang J, et al. Counter-regulatory paracrine actions of FGF-23 and 1, 25(OH)2 D in macrophages. FEBS Lett 2016; 590:53-67.
89. Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126:962-974.